Stock Movers on FDA Decision (SNTS, INO, LLY, OXGN)

K Santarus, Inc. (NASDAQ:SNTS) soared 65% to $2.78 on heavy volume after the company announced that it has signed exclusive license and supply agreements with Pharming Group NV (NYSE: PHARM).

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

The agreement allow SNTS the right to commercialize RHUCN in North America for the treatment of acute attacks of hereditary angioedema (HAE) and other future indications.

SNTS has also acquired the worldwide rights to a novel biologic drug candidate. The acquisition comes through the acquisition of Covella Pharmaceuticals, Inc., and by amending a related license agreement with Biogen Idec MA (Nasdaq: BIIB).

Inovio Pharmaceuticals, Inc. (AMEX:INO) rose 0.76% to $13.27 on heavy volume after it achieves best-in-class immune responses in VGX-3100 Phase I dose escalation study.

This vaccine targets HPV E6 and E7 proteins and is delivered via in vivo electroporation.

Inovio Pharmaceuticals, Inc., formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (DNA) vaccines, focused on cancers and infectious diseases.

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

Eli Lilly & Co. (NYSE:LLY) rose 0.30% to $42.95.after it announces that the U.S. Court of Appeals for the Second Circuit agrees with Lilly that a third-party payor suit third party class should not have been established contending that payors allegedly overpaid for Zyprexa prescriptions.

Additionally, the court ruled that plaintiffs' overpricing claims should not go forward.

OXiGENE, Inc. (NASDAQ:OXGN) rose 2% to $30.85 after announced that they have presented positive data from Phase 2/3 study of ZYBRESTAT. The median overall survival (OS) time was 5.1 months for patients who received ZYBRESTAT and chemotherapy when compared with a median survival time of 4.1 months for patients receiving chemotherapy alone.

Additionally, 23% of patients treated with ZYBRESTAT were alive at one year, compared with 9% treated with chemo alone.

About http://www.PennyStockPickReport.com

Penny Stock Pick Report offers stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks, most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.